Related Experiment Video
Updated: Sep 20, 2025
Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
Published on: July 21, 2018
LMO7-ALK Fusion in a Lung Adenocarcinoma Patient With Crizotinib: A Case Report
Yanlong Yang1, Hongbo Zheng2, Zizhe Li1
1Department of Cardiothoracic Surgery, Shantou Central Hospital, Shantou, China.
Background:
Rearrangements of the anaplastic lymphoma kinase (ALK) gene comprise a small subset of non-small cell lung cancer (NSCLC). Patients with NSCLC harboring ALK fusion proteins are sensitive to ALK tyrosine kinase inhibitors (TKIs). Various fusion partners of ALK are being discovered with the application of next-generation sequencing (NGS).
Case Presentation:
Here, we report a female patient with metastatic lung adenocarcinoma harboring LMO7-ALK (L15, A20) rearrangement revealed by NGS. The patient received crizotinib as first-line treatment and has achieved partial response with a progression-free survival over 1 year.
Conclusions:
We firstly found that the satisfactory response to crizotinib verified the oncogenic activity of LMO7-ALK fusion. Great progression and wide application of NGS facilitate the findings of rare fusion types.
Insights
Anaplastic lymphoma kinase (ALK) gene rearrangements in non-small cell lung cancer (NSCLC) are rare but treatable. Next-generation sequencing identified a novel LMO7-ALK fusion, which responded well to crizotinib treatment.
Area of Science:
- Oncology
- Genetics
- Molecular Biology
Background:
- Anaplastic lymphoma kinase (ALK) gene rearrangements occur in a small fraction of non-small cell lung cancer (NSCLC) cases.
- Patients with ALK-rearranged NSCLC demonstrate sensitivity to ALK tyrosine kinase inhibitors (TKIs).
- Next-generation sequencing (NGS) aids in the discovery of diverse ALK fusion partners.
Observation:
- A female patient with metastatic lung adenocarcinoma was diagnosed with an LMO7-ALK (L15, A20) rearrangement via NGS.
- The patient was treated with crizotinib as the initial therapy.
Findings:
- The LMO7-ALK fusion was confirmed to have oncogenic activity, as evidenced by the patient's positive response to crizotinib.
- The patient achieved a partial response and maintained progression-free survival for over one year.
Implications:
- This case highlights the clinical significance of identifying rare ALK fusion types.
- The increasing application of NGS facilitates the detection and characterization of novel oncogenic drivers in NSCLC.
- Targeted therapies like crizotinib show efficacy against specific genetic alterations in lung adenocarcinoma.
More Related Videos
09:49Oncogenic Gene Fusion Detection Using Anchored Multiplex Polymerase Chain Reaction Followed by Next Generation Sequencing
Published on: July 5, 2019
09:38Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
Published on: June 26, 2019